Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. - Marret G; Isambert N; Rezai K; Gal J; Saada-Bouzid E; Rolland F; Chausson M; Borcoman E; Alt M; Klijanienko J; Vansteene D; Guigay J; et al. (Investigational new drugs, 2021)